TetMedical
TETmedical is a clinical-stage nanomedicine company developing in vitro diagnostics on its Cornell-licensed Tethered Enzyme Technology platform. Its lead product, NSE-FAST, is a rapid blood test aiding acute ischemic stroke diagnosis for hospital emergency departments and clinical laboratories.
- Company typePrivate
- Founded2021
- HeadquartersNew Jersey, Trinidad & Tobago
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What TetMedical does
TETmedical, Inc. (also doing business as Tethered Enzyme Technologies) is a Delaware C-corp clinical-stage nanomedicine company founded in December 2021, with operations in Ithaca, NY and Fair Haven, NJ. It develops in vitro diagnostics (IVDs) built on its proprietary Tethered Enzyme Technology (TET) platform, licensed from Cornell University. The TET platform consists of "nanobots" — silica nanoparticles to which thousands of enzymes are tethered with active sites facing outward — that perform coupled catalytic reactions for biomarker detection. The architecture provides intrinsic signal amplification (each enzyme performing up to ~1,000 conversions/second), enabling detection rates the company describes as thousands of times faster than antibody assays.
The company's lead and only clinical-stage product is NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test), an IVD intended to aid diagnosis of acute ischemic stroke by measuring NSE functional enzymatic activity (rather than protein concentration) in blood plasma. By measuring activity, the test distinguishes recently released active NSE (half-life <6 hours) from inactive protein, returning results within 30 seconds to 5 minutes using standard hospital plate readers. The clinical thesis addresses the ~17% of acute ischemic strokes missed by standard CT imaging and the need to differentiate true strokes from stroke mimics before administering tPA. NSE-FAST has been studied in a pilot at Guthrie Stroke Center and a feasibility study at Weill Cornell Medicine, with a multi-center pivotal study planned for Q4 2026 and FDA marketing submission targeted for Q4 2027. A pipeline of additional TET-based assays exists in respiratory virus differential diagnostics, microRNA-based cancer tests (canine hemangiosarcoma, endometriosis, breast cancer), and at-home liver function (ALT/AST) tests.
TETmedical is pre-revenue. Its intended business model is direct sales of NSE-FAST diagnostic tests to hospital emergency departments and clinical laboratories, designed to integrate into existing stroke workflows and standard plate readers to ease adoption. Preliminary US stroke market potential is estimated at $400M–$800M annually. To date the company has been financed largely through non-dilutive sources: ~$4M in equity, ~$2M in NY State and NIH grant awards, and an underlying technology base supported by $6M+ in academic grants (including an NIH Pioneer Award); as of 2024 it was funded by three grants totaling $1.25M with applications pending for another $1.4M. The team is small (1–10 employees), led by CEO and co-founder David Fischell (a serial med-tech entrepreneur and Cornell Trustee Emeritus) alongside Cornell co-founders Alex Travis (Director) and Roy Cohen (CSO).
TetMedical firmographics
Firmographics- Name
- TetMedical
- Legal name
- TETmedical, Inc.
- Website
- https://tetmedical.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- TETmedical is a clinical-stage nanomedicine company developing in vitro diagnostics on its Cornell-licensed Tethered Enzyme Technology platform. Its lead product, NSE-FAST, is a rapid blood test aiding acute ischemic stroke diagnosis for hospital emergency departments and clinical laboratories.
- Ownership category
- akta.pro rank
TetMedical industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
Keywords
Where TetMedical is headquartered
LocationHeadquarters
- HQ city
- New Jersey
- HQ country
- Trinidad & Tobago
- HQ region
- Latin America
Offices2 records
Markets served
TetMedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- NSE-FAST Diagnostic Test Sales: Revenue from sale of the NSE-FAST in-vitro diagnostic test for stroke diagnosis to hospital emergency departments and clinical laboratories. Test is designed to be used with standard plate readers already present in hospitals.
- Pipeline Diagnostic Products: Future revenue streams from additional diagnostic products including respiratory virus differential diagnostics, microRNA-based cancer diagnostics (canine hemangiosarcoma, endometriosis, breast cancer), and at-home liver function tests (ALT/AST).
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
TetMedical product offering
Product offeringCore offering
TETmedical develops and sells rapid in-vitro diagnostic assays built on its proprietary Tethered Enzyme Technology (TET) platform, beginning with the NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test) intended to aid in the diagnosis of acute ischemic stroke by measuring NSE functional activity in blood plasma within minutes using standard hospital plate readers. The product targets emergency department clinicians and is currently in clinical studies with FDA Breakthrough Device Designation, while additional pipeline diagnostics for respiratory viruses, microRNA biomarkers, and at-home liver function (ALT/AST) tests are in development.
Product overview
TetMedical is a clinical-stage platform nanomedicine company developing in vitro diagnostics based on its proprietary Tethered Enzyme Technology (TET). The company's first product is the NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test), an IVD for stroke detection. The TET platform consists of nanobots with thousands of enzymes tethered to silica nanoparticles, enabling rapid, high-sensitivity detection. The pipeline includes tests for viral detection, microRNA biomarkers, and liver function tests.
Differentiator
Problem solved
Functional benefit
Products and services
- NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test) Rapid in-vitro diagnostic assay designed to aid in the diagnosis of acute ischemic stroke by measuring Neuron Specific Enolase functional activity in blood plasma using TET nanobots, intended for use with standard hospital plate readers in the Emergency Department alongside STAT blood work and CT imaging.
- Respiratory Virus Diagnostic Tests TET-based rapid differential diagnostic test for respiratory viral infections including influenza, COVID-19, and common cold, using RNA and DNA detection without thermocycling.
- microRNA Diagnostic Tests (Canine Hemangiosarcoma; Endometriosis; Breast Cancer) Planned TET-based point-of-care tests for specific microRNA biomarkers, with initial development in canine hemangiosarcoma and future applications in endometriosis and breast cancer.
- At-Home Liver Function Tests (ALT/AST) At-home test capable of measuring ALT and AST liver enzymes without venipuncture, using lateral flow blood separation integrated with TET biosensors.
Quantifiable outcome
- 17% of acute ischemic strokes currently missed by standard CT imaging
- +4 more outcomes
Companies that use TetMedical
Customer profileSegments3 records
Ideal customer profiles1 record
TetMedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TetMedical partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Cornell Ignite Cornell Research: Lab to Market ProgramcoreTETmedical received gap funding and commercialization support from Cornell's Ignite Cornell Research: Lab to Market program managed by Cornell Center for Technology Licensing. Program has helped 32 Ignite-supported startups secure $231 million in follow-on funding and execute 38 licenses and options since founding four years ago.
- Cornell Center for Life Science VenturescoreTETmedical moved into Cornell Center for Life Science Ventures incubator in November 2024 before relocating to new facility at 22 Thornwood Drive in Ithaca, NY. Cornell Center for Life Science Ventures manages the Ignite Cornell Research: Lab to Market program that provided gap funding and commercialization support to TETmedical.
- Biocom ConsultingminorTETmedical hired Biocom Consulting to conduct market research including 7 in-depth telephone interviews with U.S. experts (4 Emergency Department Chairs and 3 Neurologists) between January 27th and March 9th, 2023 to understand current diagnostic stroke protocols, determine current management of stroke cases, and gauge physician interest in blinded product profile.
- Guthrie Stroke CentercorePilot stroke study conducted at Guthrie Stroke Center in Pennsylvania demonstrating utility of NSE-FAST for detecting acute brain injury. Results pending publication.
- Weill Cornell MedicinecoreFollow-up feasibility study in progress at Weill Cornell Medicine to evaluate NSE-FAST in clinical settings.
- Cornell Riney Canine Health CenterminorEarly-stage product development for canine hemangiosarcoma test using microRNA biomarkers identified by Dr. Scott Coonrod at Cornell's Baker Institute for Animal Health, supported by Cornell's Riney Canine Health Center.
- Cornell UniversitycoreTETmedical emerged out of groundbreaking innovations originating at Cornell University. Co-founded by Professors Alex Travis and Roy Cohen of Cornell. Technology based on more than $6M in grant funding to professors Travis and Cohen. IP licensed from Cornell University including 4 issued and 3 pending patents. Company history states TET was transitioning from Cornell labs of Drs. Cohen and Travis to Cornell Center for Life Science Ventures incubator.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
TetMedical competitors and assessment
Company assessmentDirect peers
- BioDirection: Privately held developer of rapid point-of-care blood-based diagnostics for traumatic brain injury and stroke. Most directly comparable to TETmedical by targeting rapid biomarker-based brain-injury detection in acute care settings.
- Banyan Biomarkers: Developer of blood-based biomarker assays (GFAP, UCH-L1) for traumatic brain injury and stroke triage. Directly comparable as a competing blood-based biomarker diagnostic approach for acute brain injury in ED settings.
Broad incumbents
- Abbott Diagnostics: Global IVD leader whose i-STAT and troponin franchise is the explicit benchmark TETmedical cites for NSE-FAST. Large installed base in hospital EDs and clinical chemistry labs makes Abbott the most relevant incumbent comparator.
- Roche Diagnostics: World's largest IVD company with extensive neurology and cardiac biomarker pipelines. Comparable as a broad incumbent with the resources and channels to enter or expand in stroke biomarkers if the market validates.
- Siemens Healthineers: Major IVD player (ADVIA Centaur, Atellica) with established cardiac and neurology biomarker menu. Comparable broad incumbent with deep hospital lab penetration that could compete in rapid stroke diagnostics.
- Bio-Rad Laboratories: Established clinical diagnostics and life science research company with a broad IVD menu. Comparable as a broad incumbent with hospital lab relationships that could expand into stroke biomarkers.
Emerging players
- Quanterix: Developer of the Simoa single-molecule array platform for ultra-sensitive protein biomarker detection. Comparable as an emerging, platform-based biomarker detection company pursuing neurological disease applications with novel sensitivity claims.
- Meso Scale Diagnostics: Specialty biomarker detection platform company serving pharma, clinical research, and translational applications. Comparable as a platform biomarker detection company with multiplexed assay capabilities used in clinical research.
- Cerveau Technologies: Licensor of tau-related biomarker technology for neurodegenerative disease diagnostics. Comparable as an emerging player focused on brain-injury/neurodegeneration biomarker detection in clinical research and diagnostics.
- Cytovale: Developer of IntelliSep, a rapid cellular biomarker diagnostic for sepsis cleared by FDA. Comparable as an emerging, platform-based rapid IVD company targeting acute-care hospital decision-making with novel biomarker detection.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
TetMedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
TetMedical leadership team
Management profileNumber of profiles
Profiles12 records
TetMedical funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TetMedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TetMedical
What does TetMedical do?
TETmedical develops and sells rapid in-vitro diagnostic assays built on its proprietary Tethered Enzyme Technology (TET) platform, beginning with the NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test) intended to aid in the diagnosis of acute ischemic stroke by measuring NSE functional activity in blood plasma within minutes using standard hospital plate readers. The product targets emergency department clinicians and is currently in clinical studies with FDA Breakthrough Device Designation, while additional pipeline diagnostics for respiratory viruses, microRNA biomarkers, and at-home liver function (ALT/AST) tests are in development.
Is TetMedical a public or private company?
TetMedical is a private company. It is classified as venture growth investor backed and is currently operating.
When was TetMedical founded?
TetMedical was founded in 2021. It employs 1 to 10 people.
Where is TetMedical based?
TetMedical is headquartered in New Jersey, Trinidad & Tobago, in the Latin America region.
How does TetMedical make money?
Two revenue lines are on record. NSE-FAST Diagnostic Test Sales are the primary driver. The others are pipeline Diagnostic Products.
Who are TetMedical's main competitors?
Direct peers on record are BioDirection and Banyan Biomarkers. Broad incumbents are Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers and Bio-Rad Laboratories. Emerging players are Quanterix, Meso Scale Diagnostics, Cerveau Technologies and Cytovale.
Does TetMedical have an API?
No public API is recorded for TetMedical.
What industry is TetMedical in?
TetMedical's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 325413 and its SIC code is 2835.